- Ticker
- ADAG
- Price
- 1.84
- Stock movement down
- -0.05 (-2.65%)
- Company name
- Adagene Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Markedsverdi
- 79.90M
- Ent verdi
- -22.26M
- Pris/omsetning
- -
- Pris/bok
- 0.71
- Utbytte avkastning
- -
- Utbytte vekst
- -
- Vekst år
- -
- FCF-utbetaling
- -
- Etterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- -
- 1 års avkastning
- -74.86%
- 3 års avkastning
- -
- 5 års avkastning
- -
- 10 års avkastning
- -
Sist oppdatert: 2023-02-02
UTBYTTE
ADAG betaler ikke utbytte
VERDSETTELSE
Verdsettelsesforhold
Loading...
Verdsettelsesforhold-data
| Etterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Verdsettelse (Salg/Bokført verdi)
Loading...
Verdsettelse (Salg/Bokført verdi) data
| Pris til omsetning | - |
| Pris til bok | 0.71 |
| EV i forhold til salg | - |
ØKONOMI
Per aksje
Loading...
Per aksje-data
| Gjeldende aksje antall | 43.42M |
| EPS (TTM) | - |
| FCF per aksje (TTM) | - |
Resultatregnskap
Loading...
Resultatregnskap-data
| Inntekter (TTM) | 0.00 |
| Bruttofortjeneste (TTM) | 0.00 |
| Driftsinntekter (TTM) | 0.00 |
| Netto inntekt (TTM) | 0.00 |
| EPS (TTM) | - |
| EPS (1 år fremover) | -2.14 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | - |
| Driftsmargin (TTM) | - |
| Fortjenestemargin (TTM) | - |
Balanse
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
| Kontanter | 168.04M |
| Netto fordringer | 1.87M |
| Samlede omløpsmidler | 175.01M |
| Goodwill | 0.00 |
| Immaterielle eiendeler | 0.00 |
| Eiendom, anlegg og utstyr | 0.00 |
| Sum eiendeler | 178.56M |
| Leverandørgjeld | 4.67M |
| Kortsiktig/nåværende langsiktig gjeld | 17.00M |
| Sum kortsiktig gjeld | 56.46M |
| Sum gjeld | 65.87M |
| Aksjonærenes egenkapital | 112.68M |
| Netto varige driftsmidler | 112.68M |
Kontantstrøm
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
| Kontantstrøm fra drift (TTM) | 0.00 |
| Kapitalutgifter (TTM) | 0.00 |
| Fri kontantstrøm (TTM) | 0.00 |
| Utbetalt utbytte (TTM) | 0.00 |
Finansielle inntekter
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
| Egenkapitalavkastning | - |
| Avkastning på eiendeler | - |
| Avkastning på investert kapital | - |
| Kontantavkastning på investert kapital | - |
AKSJEINFORMASJON
Aksjediagram
Loading...
Aksjekurs-data
| Åpning | 2.00 |
| Daglig høy | 2.00 |
| Daglig lav | 1.83 |
| Daglig volum | 48K |
| Tidenes høyeste | 29.60 |
| 1 år analytikerestimat | 13.83 |
| Beta | - |
| EPS (TTM) | - |
| Utbytte per aksje | - |
| Ex-div dato | - |
| Neste dato for resultatpresentasjon | 30 Mar 2023 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| ADAG | S&P500 | |
| Nåværende prisfall fra toppnotering | -93.78% | -12.75% |
| Høyeste prisfall | -96.96% | -56.47% |
| Dato for høyeste fall | 31 Oct 2022 | 9 Mar 2009 |
| Gj.snittlig fall fra topp | -71.78% | -11.49% |
| Gj.snittlig tid til ny topp | 250 days | 13 days |
| Maks tid til ny topp | 498 days | 1805 days |
SELSKAPSOPPLYSNINGER
Markedsverdi
79.90M
Markedsverdi kategori
Small-cap
Beskrivelse
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Ansatte
259
Nettsted
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Land
USA
By
Aksjetype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
- No dose-limiting toxicities observed when ADG126 combined up to 10 mg/kg with repeat cycles, highlighting compelling safety profile with SAFEbody precision masking technology - - Partial responses c...
9. januar 2023
SAN DIEGO and SUZHOU, China, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announce...
5. januar 2023
SAN DIEGO and SUZHOU, China, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announce...
16. desember 2022
SAN DIEGO and SUZHOU, China, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announce...
21. november 2022
- Interim phase 1b/2 data report safety profile of ADG116 across dosing levels, with repeat dosing of more than four cycles both as monotherapy and in combination with anti-PD-1 therapy - - Results in...
10. november 2022
- NEObody technology platform enables dynamic targeting of a distinct epitope of CTLA-4 for enhanced safety and efficacy - - Data from phase 1b/2 studies in heavily pre-treated patients showcase diffe...
11. oktober 2022
- Best-in-class profile demonstrated with repeat dosing across dose levels - - Antitumor activity observed in cold tumors with steady accumulation of activated ADG126 - - On track in 2022 to report re...
10. september 2022
– Topline data for anti-CTLA-4 antibody, ADG116, shows compelling clinical safety and complete and partial responses as both a single agent and in combination with anti-PD-1 therapy; results to be pre...
30. august 2022
SAN DIEGO and SUZHOU, China, June 29, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today an...
29. juni 2022
Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced the publication of data showing the potential best-in-c...
27. mai 2022
Neste side